Qure AI vs Rayscape (2026)
Two chest imaging companies built for settings where specialist reading capacity is short. Qure sells chest X-ray, head CT and chest CT products in more than 105 countries by its own count, with tuberculosis screening products the company says are WHO evaluated, care platforms for health programs, and US clearances that include qXR-Detect, a concurrent reading aid with a Predetermined Change Control Plan. Rayscape is smaller, with independent evaluation in a tuberculosis screening context and longitudinal comparison against a patient's prior scans built in. Both offer on premise deployment, which matters where images cannot leave the country. Do not compare them on findings counts, which each counts differently. Compare them on performance for the findings your population presents with, at your prevalence.
- Tuberculosis screening evidence from independent studies in several countries and a 2025 systematic review, plus program evaluations and a cost effectiveness study in Nigeria.
- US clearances for chest X-ray and head CT, including a cleared change plan for qXR-Detect.
- Care platforms around the reads: qTrack for tuberculosis care cascades and Aira for health programs.
- Independent evaluation in a tuberculosis screening context, a harder test than a retrospective reader study.
- Longitudinal comparison across a patient's prior scans, so change over time is visible rather than each study read in isolation.
- On premise and cloud integration both offered.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Qure AI and Rayscape are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Qure AI | Rayscape |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2016 | 2019 |
| Headquarters | Mumbai, India | Timisoara, Romania |
| Website | qure.ai | rayscape.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Qure.ai, founded in 2016 in Mumbai with a US entity in New York, sells radiology AI in more than 105 countries through more than 5,500 sites by its own count. Its products are qXR for chest X-ray (detection, reporting, lung nodules and tuberculosis screening), qER for head CT in stroke and trauma, qCT for chest CT nodules and lung cancer, qMSK for musculoskeletal X-ray, and heart failure detection.
Source: AI Health Index, August 2026
Romanian imaging AI company based in Timisoara whose Rayscape CXR analyzes chest X-rays, detecting and localizing 148 findings across 17 clinical classes, including tuberculosis, with bone suppressed views, an automatic cardiothoracic ratio and a normal or abnormal flag for worklist prioritization, and whose lung CT product detects nodules and compares them against a patient's prior scans. Its tuberculosis detection was evaluated independently in a South African tuberculosis prevalence survey published in The Lancet Digital Health in 2024.
Source: AI Health Index, August 2026
Questions buyers ask
How do Qure AI and Rayscape work with the EHR?
For Qure AI, the qXR page promises zero integration effort and deployment on cloud or on premise, the company says its software works with new and old X-ray systems, and the qXR-Detect summary describes results returned to radiology software or the X-ray console; qXR-LN is cleared for use with any DICOM viewer or PACS.
Rayscape CXR integrates with the archive over DICOM, on premises or with a cloud archive, returning annotated images and structured outputs inside the native radiology viewer without a separate workspace, and sites can configure outputs, thresholds and visualization to their own reporting standards. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Qure AI and Rayscape priced and sold?
In Qure AI's case, the portfolio makes the gap matter. Qure sells chest X-ray, head and chest CT and musculoskeletal products under ten US clearances, plus tuberculosis care cascades and the Aira care delivery platform, and nothing says whether indications are licensed singly, bundled by modality or sold as a platform.
The company's site has a pricing and plans page, and its AWS Marketplace listing for Rayscape CXR shows a free subscription with no end date alongside a 30 day money back guarantee on the current annual term, which suggests a paid annual contract behind the listing without stating its price or unit. The product can be procured through the marketplace and directly. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Qure AI and Rayscape handle patient data?
Qure's Security and Regulatory page says data is de-identified before it leaves a covered entity's premises for cloud processing, and that on-premise installations may process identifiable images only on servers the customer owns and operates.
In Rayscape's case, the company's AWS Marketplace listing describes the product as software as a service, which sits uneasily with data never leaving the institution, and nothing says which deployments the commitment covers. Support, diagnostic and incident access usually carries exceptions. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Qure AI and Rayscape cover?
Qure covers chest X-ray, head and chest CT and musculoskeletal X-ray, sold to hospitals, imaging centers, teleradiology services, immigration screening and public health programs in more than 105 countries.
With Rayscape, the tuberculosis use has independent validation in a South African prevalence survey (The Lancet Digital Health, 2024), a population screening setting; the broader findings set and the CT product have no published per finding validation. The company reports clinical use at more than 300 sites in 18 countries, and its customer stories describe emergency and outpatient deployments. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Rayscape's record has not yet been reviewed on this site, so its side of this page rests on the build record. The findings counts these vendors publish are not comparable, because each counts differently and per finding performance varies within any such list.
Prevalence is decisive here. A model validated in a high tuberculosis burden setting produces very different positive predictive values in a low prevalence one, so ask both for results in a population like yours. Qure markets sorting out unremarkable chest X-rays without saying who reads the studies set aside. Neither publishes pricing.